What Happened?
Menlo Park, CA-based Spirox Appointed Duke Rohlen as Chief Executive Officer
About the Company
Spirox is a Menlo Park, CA-based medical device company. The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization.
About the Person
Over 15 years of experience as an executive in medical device companies. Currently Duke serves as Chairman and CEO of Spirox, Inc. and Chairman and CEO of Advanced Cardiac Therapeutics. Prior to Spirox and Advanced Cardiac Therapeutics, Duke served as founder and CEO of CV Ingenuity where he raised $30.0 million of venture capital prior to selling the company to Covidien (now Medtronic) in 2013 for ~$300.0 million. Prior to CV Ingenuity, Duke served in a variety of roles at FoxHollow Technologies prior to being named President. Duke helped drive annual sales to ~$200.0 million, helped the Company through an IPO, conceived of and structured a $300.0 million collaboration with Merck Pharmaceuticals, and ultimately led the sale of the company to EV3 (now Medtronic) for $780.0 million in 2008. Prior to working at FoxHollow, Duke held senior management positions at two other medical technology companies and served as an entrepreneur-in-residence at the private equity firm, Alta Partners. Mr. Rohlen began his professional career as the founder and President of a 9 unit, ~$20.0 million per year restaurant company. Mr. Rohlen received an M.B.A. from Harvard Business School and a B.A. from Stanford University.
Info Source
Press Release
Short Profile